Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 12.8× Iovance Biotherapeutics Inc. Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and MONDELEZ INTERNATIONAL INC Common Stock for 107 Days on average.
| IOVA | MDLZ | |
|---|---|---|
Market Cap | $6.04B | $77.43B |
Volume | 14,805,993 | 7,695,104 |
Sector | Health | Consumer Staples |
52-Week High | $14.82 | $64.99 |
52-Week Low | $1.81 | $51.51 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $5.97B | $97.78B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mondelez International (MDLZ) trades at $60.67, up 2.17% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.73 exceeding expectations. Revenue growth continues, reaching $38.54B in 2025, while maintaining solid profitability with 8.86% net margin. Recent dividend increase to $0.52 per share and positive news coverage highlight management's confidence in sustained performance.
MDLZ presents a compelling investment case with 76% analyst buy ratings and $70.29 consensus target, offering 16% upside. The company's global brand strength and emerging market momentum support growth, though cocoa cost pressures and competitive snack market pose risks. Cash flow stability and shareholder returns through dividends provide defensive characteristics in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
